What is the role of intravenous (IV) therapy in managing stress?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 9, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

"Antistress IV Therapy" Has No Evidence-Based Role in Stress Management

There is no established medical indication for intravenous therapy in the treatment of stress or anxiety disorders, and such interventions are not supported by clinical guidelines or evidence-based medicine. The term "antistress IV therapy" appears to reference commercially marketed wellness infusions (often containing vitamins, minerals, or other compounds) that lack rigorous scientific validation for stress reduction.

Evidence-Based Treatments for Stress and Anxiety

First-Line Psychotherapeutic Interventions

Cognitive-behavioral therapy (CBT) is the psychotherapy with the strongest evidence base for anxiety and stress-related disorders. 1

  • CBT effectively reduces psychological symptoms including anxiety and depression, as well as physical symptoms like pain and fatigue. 1
  • A Cochrane systematic review of 28 RCTs (n=3,940) demonstrated that CBT favorably addresses anxiety, depression, and mood disturbance in patients with cancer-related distress. 1
  • For generalized anxiety disorder, CBT shows large effect sizes (Hedges g = 1.01; 95% CI, 0.44 to 1.57) compared with placebo. 2
  • Mindfulness-based stress reduction (MBSR) was found noninferior to escitalopram in a randomized trial of 276 adults with anxiety disorders, with mean CGI-S score reductions of 1.35 for MBSR versus 1.43 for escitalopram (difference -0.07; 95% CI, -0.38 to 0.23). 3

First-Line Pharmacologic Interventions

Selective serotonin reuptake inhibitors (SSRIs) such as sertraline and serotonin-norepinephrine reuptake inhibitors (SNRIs) such as venlafaxine extended-release are first-line pharmacotherapy for anxiety disorders. 2

  • SSRIs and SNRIs demonstrate small to medium effect sizes compared with placebo (generalized anxiety disorder: SMD -0.55; 95% CI, -0.64 to -0.46). 2
  • Antidepressants are prescribed to approximately 15.6% of patients with significant distress, with SSRIs being the most widely used agents. 1
  • Benzodiazepines may be used for acute anxiety but carry risks of respiratory depression and require careful monitoring. 4

Supportive and Complementary Interventions

Exercise, particularly aerobic training, should be systematically recommended as adjunctive treatment for stress and anxiety. 5

  • Aerobic exercise may reduce depression in patients with stress-related conditions (SMD 0.25; 95% CI, 0.00-0.50; P=.05). 1
  • Exercise improves cardiovascular fitness, strength, and quality of life while positively impacting mental health outcomes. 1

Complementary therapies including meditation, yoga, relaxation with imagery, massage, and music therapy may be helpful for stress reduction. 1

  • A meta-analysis of 16 RCTs (n=930) showed yoga may reduce depression (SMD -0.17; P<.001) and anxiety (SMD -0.98; P<.001). 1
  • Music therapy benefits patients with anxiety across 52 trials (n=3,731; P<.001). 1

Critical Pitfalls to Avoid

Do not pursue unproven "wellness" IV therapies as substitutes for evidence-based treatments. These interventions lack regulatory oversight, carry risks of infection and adverse reactions, and divert patients from effective care. 1

Patients presenting with stress or anxiety require proper screening and diagnosis using validated instruments such as the Generalized Anxiety Disorder-7 scale (sensitivity 57.6-93.9%; specificity 61-97%). 2

Treatment selection should prioritize patient preference between psychotherapy and pharmacotherapy, as both have comparable efficacy. A meta-analysis showed patients were more willing to participate in telephone-delivered interventions versus in-person (P=.031). 1

When using pharmacotherapy, monitor for adverse events. In the MBSR versus escitalopram trial, 78.6% of escitalopram patients experienced study-related adverse events versus 15.4% in the MBSR group, with 8% dropping out due to adverse events in the medication arm. 3

Practical Implementation Algorithm

  1. Screen for anxiety disorders using validated tools (GAD-7) 2
  2. Provide psychoeducation about stress physiology and treatment rationale 5
  3. Offer first-line treatment choice:
    • CBT (individual or group format, including telephone/video delivery) 1
    • SSRI/SNRI pharmacotherapy (sertraline, venlafaxine XR) 2
    • MBSR as alternative to medication 3
  4. Add adjunctive interventions:
    • Aerobic exercise prescription 1, 5
    • Relaxation techniques (diaphragmatic breathing, progressive muscle relaxation) 1, 6
    • Complementary therapies (yoga, meditation, music therapy) 1
  5. Reassess at 8 weeks and adjust treatment based on response 3, 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Medication Options for Acute Agitation Without IV Access

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.